- Home
- MIRA vs ATRA Comparison
MIRA vs ATRA Comparison
Compare MIRA & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | ATRA |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.0M | 38.9M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MIRA | ATRA |
|---|---|---|
| Price | $1.09 | $5.05 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 136.0K | 66.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.95 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $3.92 |
| 52 Week High | $2.45 | $19.15 |
Technical Indicators
Market Signals| Indicator | MIRA | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 49.37 |
| Support Level | $0.99 | $4.22 |
| Resistance Level | $1.24 | $5.31 |
| Average True Range (ATR) | 0.05 | 0.39 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 73.30 | 57.35 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).